Accéder au contenu
MilliporeSigma
Toutes les photos(1)

Documents

Y0001400

Vigabatrin

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

(±)-Vigabatrin, (R,S)-4-Amino-5-hexenoic acid, (±)-γ-Vinyl-GABA, (±)-4-Aminohexenoic acid

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C6H11NO2
Numéro CAS:
68506-86-5
Poids moléculaire :
129.16
Numéro MDL:
MFCD00274577
Code UNSPSC :
41116107
ID de substance PubChem :
329831404
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

vigabatrin

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

NC(CCC(O)=O)C=C

InChI

1S/C6H11NO2/c1-2-5(7)3-4-6(8)9/h2,5H,1,3-4,7H2,(H,8,9)

Clé InChI

PJDFLNIOAUIZSL-UHFFFAOYSA-N

Informations sur le gène

human ... ABAT(18)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Vigabatrin EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Actions biochimiques/physiologiques

Irreversible GABA transaminase inhibitor. Increases intracellular concentration of GABA in nerve endings; possesses antiepileptic activity.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Pictogrammes

Health hazard
GHS08

Mention d'avertissement

Danger

Mentions de danger

H372

Classification des risques

STOT RE 1

Organes cibles

Eyes,Central nervous system

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 1

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Choose from one of the most recent versions:

Certificats d'analyse (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Eija Gaily
Expert review of neurotherapeutics, 12(3), 275-286 (2012-03-01)
Infantile spasms syndrome (IS) (also known as West syndrome) is an epileptic encephalopathy with a heterogeneous etiology. One of the most common specific causes is tuberous sclerosis, diagnosed in almost 10% of the affected infants. Adrenocorticotropic hormone or steroids have
L James Willmore et al.
Epilepsia, 50(2), 163-173 (2009-02-21)
Vigabatrin (VGB) is a structural analogue of gamma-aminobutyric acid (GABA) that irreversibly inhibits GABA-transaminase (GABA-T), increasing brain levels of GABA. VGB is under assessment for treatment of infantile spasms (IS) and refractory complex partial seizures (CPS). Response can be rapid
L Carmant
Acta neurologica Scandinavica. Supplementum, (192)(192), 36-47 (2011-11-09)
Infantile spasms (IS) are a unique and severe form of epilepsy associated with poor neurologic and developmental outcomes. The refractory spasms and abnormal electroencephalogram (EEG) patterns associated with the condition are believed to have a progressively detrimental impact. Therefore, rapid
Melissa J Maguire et al.
Epilepsia, 51(12), 2423-2431 (2010-11-13)
Vigabatrin is an efficacious antiepileptic drug licensed as add-on therapy in refractory epilepsy and used in infantile spasms. Eight years after licensing, there emerged a strong and possibly causative association with bilateral visual field loss. We report a systematic review
Karla Hemming et al.
The Cochrane database of systematic reviews, 1(1), CD007302-CD007302 (2013-02-27)
Epilepsy is a common neurological condition which affects between 0.5% and 1% of the population. Approximately 30% of people with epilepsy do not respond to treatment with currently available drugs. The majority of these people have partial epilepsy. Vigabatrin is
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique